# Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

> **NCT02339168** · PHASE1 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Metformin Hydrochloride

## Key facts

- **NCT ID:** NCT02339168
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-22
- **Primary completion:** 2024-10-15
- **Final completion:** 2025-02-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339168, "Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02339168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*